Clinical trial

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or…

NCT00174733 · Sanofi, Industry · Completed

Key facts

NCT number NCT00174733
Title Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
Official title A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in…
Lead sponsor Sanofi, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Asthma
Intervention type Drug
Interventions Ciclesonide (XRP1526)
Enrollment 456
Start date Jul 1, 2005
Primary completion Feb 1, 2006
Completion Feb 1, 2006
First posted Sep 15, 2005
Last update posted Apr 8, 2009
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies